Literature DB >> 30524908

Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Melody Smith1, Elena García-Martínez2, Michael R Pitter1, Jitka Fucikova3,4, Radek Spisek3,4, Laurence Zitvogel5,6,7,8, Guido Kroemer9,10,11,12,13,14,15, Lorenzo Galluzzi9,16,17.   

Abstract

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

Entities:  

Keywords:  Ampligen®; Hiltonol®; SD-101; bacillus Calmette-Guérin; imiquimod; motolimod

Year:  2018        PMID： 30524908      PMCID： PMC6279325          DOI： 10.1080/2162402X.2018.1526250

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  242 in total

1.  Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.

Authors:  Jungwoo Choe; Matthew S Kelker; Ian A Wilson
Journal:  Science       Date:  2005-06-16       Impact factor: 47.728

Review 2.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

3.  Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

Authors:  Stephen V Liu; D Ross Camidge; Scott N Gettinger; Giuseppe Giaccone; Rebecca S Heist; F Stephen Hodi; Neal E Ready; Wei Zhang; Jeffrey Wallin; Roel Funke; Daniel Waterkamp; Paul Foster; Koho Iizuka; John Powderly
Journal:  Eur J Cancer       Date:  2018-07-24       Impact factor: 9.162

4.  Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.

Authors:  Christian Hotz; Marina Treinies; Ines Mottas; Laurin C Rötzer; Anne Oberson; Lorenzo Spagnuolo; Maurizio Perdicchio; Thibaud Spinetti; Tina Herbst; Carole Bourquin
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

5.  The toll-like receptor ligands Hiltonol® (polyICLC) and imiquimod effectively activate antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii).

Authors:  Amanda L Patchett; Cesar Tovar; Lynn M Corcoran; A Bruce Lyons; Gregory M Woods
Journal:  Dev Comp Immunol       Date:  2017-07-06       Impact factor: 3.636

6.  Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4.

Authors:  Alexzander Asea; Michael Rehli; Edith Kabingu; Jason A Boch; Olivia Bare; Philip E Auron; Mary Ann Stevenson; Stuart K Calderwood
Journal:  J Biol Chem       Date:  2002-02-08       Impact factor: 5.157

Review 7.  Current clinical trials testing combinations of immunotherapy and radiation.

Authors:  Marka Crittenden; Holbrook Kohrt; Ronald Levy; Jennifer Jones; Kevin Camphausen; Adam Dicker; Sandra Demaria; Silvia Formenti
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Intravesical ALT-803 for BCG-unresponsive Bladder Cancer - A Case Report.

Authors:  Jeffrey Huang; John Schisler; Hing C Wong; Charles J Rosser; Joseph Sterbis
Journal:  Urol Case Rep       Date:  2017-06-08

10.  Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.

Authors:  Evan Gomes-Giacoia; Makito Miyake; Steve Goodison; Aravindhan Sriharan; Ge Zhang; Lijing You; Jack O Egan; Peter R Rhode; Alexander S Parker; Karl X Chai; Hing C Wong; Charles J Rosser
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240
View more
  59 in total

Review 1.  Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.

Authors:  Geoffrey M Lynn; Richard Laga; Christopher M Jewell
Journal:  Cancer Lett       Date:  2019-06-08       Impact factor: 8.679

Review 2.  The expanding role for small molecules in immuno-oncology.

Authors:  Rienk Offringa; Lisa Kötzner; Bayard Huck; Klaus Urbahns
Journal:  Nat Rev Drug Discov       Date:  2022-08-18       Impact factor: 112.288

3.  TLR agonist rMBP-NAP inhibits B16 melanoma tumor growth via induction of DCs maturation and T-cells cytotoxic response.

Authors:  Jiaojiao Liu; Cong Ding; Xiaolong Wang; Lu Yang; Xin Liu; Qiaozhen Kang
Journal:  Cytotechnology       Date:  2022-07-02       Impact factor: 2.040

4.  Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy.

Authors:  Diana Corogeanu; Sandra S Diebold
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

Review 5.  The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy.

Authors:  Lingling Huang; Xiaoyan Ge; Yang Liu; Hui Li; Zhiyue Zhang
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

6.  Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.

Authors:  Hua Zhang; Wei-Lun Tang; Azadeh Kheirolomoom; Brett Z Fite; Bo Wu; Kenneth Lau; Mo Baikoghli; Marina Nura Raie; Spencer K Tumbale; Josquin Foiret; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; R Holland Cheng; Alexander D Borowsky; Katherine W Ferrara
Journal:  J Control Release       Date:  2020-11-13       Impact factor: 9.776

7.  Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity.

Authors:  Rosmely Hernandez; Kevin H Toomer; Janika Põder; Alicia Santos Savio; Sunnie Hsiung; Thomas R Malek
Journal:  Cancer Immunol Immunother       Date:  2020-10-10       Impact factor: 6.968

Review 8.  Tumor-associated myeloid cells: diversity and therapeutic targeting.

Authors:  Alberto Mantovani; Federica Marchesi; Sebastien Jaillon; Cecilia Garlanda; Paola Allavena
Journal:  Cell Mol Immunol       Date:  2021-01-20       Impact factor: 11.530

Review 9.  Toll-Like Receptor-Based Strategies for Cancer Immunotherapy.

Authors:  Saghar Pahlavanneshan; Ali Sayadmanesh; Hamidreza Ebrahimiyan; Mohsen Basiri
Journal:  J Immunol Res       Date:  2021-05-22       Impact factor: 4.818

10.  Delivery of toll-like receptor agonists by complement C3-targeted liposomes activates immune cells and reduces tumour growth.

Authors:  Alexandra Francian; Ashley Widmer; Troy Olsson; Marisabel Ramirez; Darion Heald; Keaton Rasic; Luke Adams; Holly Martinson; Max Kullberg
Journal:  J Drug Target       Date:  2021-02-01       Impact factor: 5.016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.